# PT-141 (Bremelanotide): A Regulatory-Careful Research Digest > PT-141 (bremelanotide) is a central melanocortin MC4R agonist approved for hypoactive sexual desire disorder in premenopausal women only. A cited, approval-aware literature digest. A compliance-minded reading of what the literature and the label actually establish: the central mechanism, the trials in women, the dose of record, and the line where the approved use ends and off-label or research-chemical use begins. ## The short version PT-141 — also called bremelanotide — is a small synthetic peptide (a short chain of amino acids built in a lab) that copies part of a natural body signal. It works in the brain, not in the bloodstream the way most erection drugs do. It switches on a brain receptor (a docking site on a nerve cell) called MC4R, which sits in circuits that govern sexual desire [1]. In 2019 a version of this peptide was approved by the U.S. FDA — but only for one specific group: premenopausal women diagnosed with hypoactive sexual desire disorder (HSDD), a persistent lack of desire that causes real distress [3][7]. Every other use you may read about — men, postmenopausal women, "performance," appetite — is off-label or still investigational [7]. The benefit measured in trials was real but modest, and nausea was common [3][4]. Material sold online as "PT-141 research chemical" sits outside that approval entirely, with no oversight of what is in the vial [7]. What the studies found, what people report — including the downsides — and who has a reason to be careful is laid out on [PT-141 effects](/effects). ## What is PT-141 PT-141 is a synthetic cyclic heptapeptide (a ring-shaped chain of seven amino acids) and an agonist — a key that switches a receptor on — at the melanocortin receptors MC3R and MC4R, which sit mostly in the brain [1]. It is a laboratory analogue of alpha-MSH, a natural signaling peptide the body makes from a larger precursor protein. Its international nonproprietary name is bremelanotide. The mechanism is the headline. Unlike the more familiar erectile-dysfunction pills, which act on blood vessels at the periphery, PT-141 acts centrally — on the neural circuitry of sexual motivation itself [1]. Systemic dosing in rats and nonhuman primates produced erections and lit up hypothalamic neurons (measured as increased c-Fos, a marker of nerve-cell activation), evidence the effect begins in the brain [1]. In men with erectile dysfunction, early dose-ranging work produced rapid, dose-dependent erectile activity [1]. ## What is PT-141 peptide Asked another way: the "PT-141 peptide" is the same molecule under its chemistry name. It is a cyclic lactam — the seven-amino-acid ring is closed by a chemical bridge between two side chains — which makes it more stable than a straight-chain peptide [7]. Structurally it is a close relative of an older melanocortin peptide, with the tail end changed from an amide to an acid group. This stability is part of why the approved product can be given as an as-needed subcutaneous injection rather than a continuous infusion. After a dose, peak blood levels arrive within about half an hour to an hour, and the drug clears with a terminal half-life of roughly 2.7 hours [7]. None of that is a dosing instruction — it is the pharmacology of record, drawn from the prescribing information. ## The approval boundary, stated plainly This is the fact the rest of the site is organized around. Bremelanotide was approved on June 21, 2019 (NDA 210557) for acquired, generalized HSDD in premenopausal women — and for nothing else [7]. It is not approved for men. It is not approved for postmenopausal women. It is not approved to enhance performance, and it is not an appetite or weight drug, even though the same MC4R it acts on also sits in appetite circuits [7]. That narrowness is easy to lose online, where PT-141 is discussed as a general-purpose libido or erection compound. The published evidence does include male erectile-dysfunction data — but that line of development did not lead to an approval for men, and treating it as if it did misstates the record [7]. Where this digest describes male, off-label, or research-chemical use, it labels it as such. ## How this digest reads the evidence PT-141 is unusual in this field: it has a real regulatory dossier — two large Phase 3 trials, a 52-week extension, mechanistic brain imaging, and a published label — alongside the looser claims that circulate around any "research peptide" [3][4][5][7]. That contrast is the editorial job here. Each claim is tied to its source and to its regulatory standing. A finding from the [PT-141 research](/research) literature is read as evidence; the approved indication is read as the approved indication; an off-label or research-chemical use is flagged as outside the approval. The lens this site leads with is the female-sexual-function evidence — the trials and brain-imaging work in women — because that is where the approval and the strongest human data live. The [PT-141 references](/references) page lists every study cited. --- A regulatory-careful reading room on PT-141 (bremelanotide): the single 2019 approval for premenopausal HSDD held distinct from every off-label and research-chemical use, each figure logged to the trials or the FDA label — a reading desk organized around the prescription record, never a place that writes, fills, or fulfils one.